COSMOS Pharmaceutical Corporation (3349.T)

9053.0035.00 (-0.39%)

COSMOS Pharmaceutical Corporation (3349.T) stock comprehensive Cash Flow Analysis including operating cash flow, investing cash flow, financing cash flow, free cash flow, cash flow from operations, cash flow from investing, cash flow from financing. Compare cash flow against peers/competitors, industry and sector standards.

Low Bankruptcy RiskLow ProfitabilityEfficient OperationsModerate GrowthModerate QualityAdequate Dividend ProfileIndustry Rank: 67.57%Sector Rank: 75.68%

JPX - Healthcare - Medical - Pharmaceuticals | Market Cap: 717.52B | Next Earnings Date: 14 Oct 2025

Day's Range

8935.00 - 9125.00

52-Week Range

6347.00 - 10045.00

Volume

380.0K / 335.9K (Avg.)

P/E Ratio | EPS

23.15 | 391.09

Trending:

3349.T Cash Flow Analysis - Compare Against 3088.T

Comparison against 3088.T

None 3391.T 3141.T 3088.T 2127.T 9843.T

Reveals whether the business's core operations generate sufficient cash to cover expenses, fund growth, and return capital to shareholders. Sustainable free cash flow is often a key indicator of long-term value creation.

Operating Cash Flow per Share

223.46

Increased from previous period

OCF/share above 1.5x 3088.T's 9.55. David Dodd would verify if a competitive edge drives superior cash generation.

Free Cash Flow per Share

185.38

Increased from previous period

FCF/share above 1.5x 3088.T's 7.12. David Dodd would confirm if a strong moat leads to hefty cash flow.

Capex-to-Operating Cash Flow

17.04%

Increased from previous period

Capex/OCF 50–75% of 3088.T's 25.48%. Bruce Berkowitz might consider it a moderate capital edge.

Income Quality Ratio (OCF / Net Income)

2.88

Increased from previous period

Ratio above 1.5x 3088.T's 0.67. David Dodd would see if the business collects cash far more effectively.

Operating Cash Flow-to-Sales Ratio

13.94%

Increased from previous period

OCF-to-sales above 1.5x 3088.T's 3.76%. David Dodd would confirm if unique cost controls or pricing lead to strong cash conversion.

Select Chart Metric:

3349.T Cash Flow Analysis - Compare Against 3088.T

Comparison against 3088.T

None 3391.T 3141.T 3088.T 2127.T 9843.T

Operating Cash Flow per Share

223.46

Increased from previous period

OCF/share above 1.5x 3088.T's 9.55. David Dodd would verify if a competitive edge drives superior cash generation.

Free Cash Flow per Share

185.38

Increased from previous period

FCF/share above 1.5x 3088.T's 7.12. David Dodd would confirm if a strong moat leads to hefty cash flow.

Capex-to-Operating Cash Flow

17.04%

Increased from previous period

Capex/OCF 50–75% of 3088.T's 25.48%. Bruce Berkowitz might consider it a moderate capital edge.

Income Quality Ratio (OCF / Net Income)

2.88

Increased from previous period

Ratio above 1.5x 3088.T's 0.67. David Dodd would see if the business collects cash far more effectively.

Operating Cash Flow-to-Sales Ratio

13.94%

Increased from previous period

OCF-to-sales above 1.5x 3088.T's 3.76%. David Dodd would confirm if unique cost controls or pricing lead to strong cash conversion.

Select Chart Metric: